We present here the final results of the irinotecan versus IrPan comparison for patients with KRAS wild-type tumours who had not received previous anti-EGFR therapy; findings from the irinotecan versus irinotecan plus ciclosporin comparison will be reported elsewhere.4 Here, KRAS is linked to neoplasm.